Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation (DREPA COAG)

Civil Hospices of Lyon

Status

Not yet enrolling

Conditions

Sickle Cell Disease (SCD)

Treatments

Other: blood sampling

Study type

Observational

Funder types

Other

Identifiers

NCT06619093

69HCL24_0679

Details and patient eligibility

About

Sickle cell disease is characterized by chronic hemolytic anemia and blood rheological alterations. In addition, blood coagulation abnormalities have been reported in patients with sickle cell disease and hemolysis-derived products could be involved. The investigators hypothesized that patients with sickle cell disease and severe hemolysis (Lactate Dehydrogenase level > 484 IU/L) could have an increased risk of hypercoagulable state and subsequent thromboembolic complications.

Enrollment

200 estimated patients

Sex

All

Ages

8+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged 8 years or older
Under clinical follow-up for a diagnosis of sickle cell disease, specifically genotypes S/S, S/beta0, or S/C
Patient covered by a social security or equivalent health insurance plan
Collection of the non-opposition for adults
Information of the minor and collection of the non-opposition from both parents

Exclusion criteria

Patient who has undergone a transfusion or therapeutic phlebotomy within the 3 months prior to inclusion
Patient participating in another interventional research protocol that may interfere with the present protocol (at the investigator's discretion)
Patient under guardianship, curatorship, or legal protection
Patient subject to a legal protection measure
Person admitted to a health or social care institution for purposes other than research